About Comet Therapeutics
Comet Therapeutics is a company based in Cambridge (United States) founded in 2017 by Enej Kuscer was acquired by VectivBio in August 2021. Comet Therapeutics has raised $28.5 million across 1 funding round from investors including Canaan, VectivBio and Mission BioCapital. Comet Therapeutics operates in a competitive market with competitors including Alnylam, Ultragenyx, BioMarin Pharmaceutical, Mirum Pharmaceuticals and Homology Medicines, among others.
- Headquarter Cambridge, United States
- Founders Enej Kuscer
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Comet Therapeutics
Comet Therapeutics has successfully raised a total of $28.5M through 1 strategic funding round. The most recent funding activity was a Series A round of $28.5 million completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Comet Therapeutics
Comet Therapeutics has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Canaan, VectivBio and Mission BioCapital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in life science startups are made by Mission BioCapital.
|
Locked | Locked | Locked | |
|
Canaan is recognized as an early-stage venture capital firm.
|
Locked | Locked | Locked | |
|
Sofinnova Partners is focused on life sciences and healthcare investments.
|
Locked | Locked | Locked |
Investor details for Comet Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Comet Therapeutics
Investment portfolio details for Comet Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Comet Therapeutics
Detailed financials for Comet Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Comet Therapeutics Comparisons
Peer comparison for Comet Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Comet Therapeutics
Comet Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Ultragenyx, BioMarin Pharmaceutical, Mirum Pharmaceuticals and Homology Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for rare genetic diseases
|
|
| Locked | Locked | Locked |
Orally deliverable bradykinin B2 antagonists are developed for hereditary angioedema.
|
Detailed competitors of Comet Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Comet Therapeutics
Complete news archive for Comet Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Comet Therapeutics
Comet Therapeutics was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Comet Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Comet Therapeutics is a funded company, having raised a total of $28.5M across 1 funding round to date.
Comet Therapeutics was founded in 2017 and is based in Cambridge, United States. Therapies for neurological diseases are developed through enzyme substitution approaches. Orphan neurological disorders are addressed via Coenzyme-A substitution methods. The CoEnzyme metabolism (CoMET) platform has been established to restore dysregulated CoEnzyme A metabolism in affected patients. Operations center on advancing treatments within the biotechnology sector for rare conditions.
Comet Therapeutics's top competitors include Alnylam, UniQure and BioMarin Pharmaceutical.
Comet Therapeutics has 5 investors. Key investors include Canaan, VectivBio, Mission BioCapital, Sofinnova Partners, and Inkef.